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The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has introduced a four-
stage classification of chronic obstructive pulmonary disease (COPD) severity. The present
study investigated the discriminatory capacity of the GOLD classification for health status
outcomes in patients with COPD. An additional analysis was performed to investigate the
discriminatory capacity of a multidimensional staging system, i.e. the Body-Mass Index,
Degree of Airflow Obstruction and Dyspnea, and Exercise Capacity Index (BODE index) for
the outcome of quality of life.
Retrospective analysis was performed on 253 COPD patients (30% stage II, 48% stage III, 22%
stage IV), referred for outpatient pulmonary rehabilitation. Pulmonary function, exercise
capacity, dyspnoea and quality of life were evaluated. Analyses of variance were used to
detect differences between GOLD stages and BODE index quartiles, and scatterplots of
individual responses were produced as well.
The GOLD classification discriminated between stages for pulmonary function (po0.001),
exercise capacity (po0.001), dyspnoea (po0.001) and the activities section (p ¼ 0.001) of
the St. George Respiratory Questionnaire (SGRQ). The BODE index discriminated between
quartiles for the activities section (po0.001), impacts section (p ¼ 0.04) and the total
score (p ¼ 0.01) of the SGRQ. Scatterplots revealed marked inter-individual variationElsevier Ltd. All rights reserved.
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The GOLD classification in pulmonary rehabilitation 163within each GOLD stage or BODE index quartile, and considerable overlap between stages
for all health status outcomes.
These findings show that the GOLD classification indeed can be used to discern groups of
COPD patients, but due to large inter-individual variability it does not seem adequate as a
basis for individual management plans in rehabilitation. The BODE index appeared to
discriminate slightly better for quality of life, however, it still leaves a significant part of
the variance unexplained.
& 2007 Elsevier Ltd. All rights reserved.Introduction
The major hallmark of chronic obstructive pulmonary
disease (COPD) is incompletely reversible, expiratory airflow
limitation. Forced expiratory volume in 1 s (FEV1) is used to
determine disease severity in COPD and traditionally formed
the basis of different classification systems.1,2 Quantifica-
tion of disease severity based on FEV1 undoubtedly has the
advantage of simplicity. However, FEV1 does not fully
describe other important pathophysiological changes of
the pulmonary tract such as (dynamic) hyperinflation and
gas exchange abnormalities.3 Moreover, in COPD a variety of
extra-pulmonary impairments may be present as well,
significantly contributing to exertional dyspnoea and ex-
ercise limitation, independent of the airflow limitation.4
These impairments form important focal points in pulmon-
ary rehabilitation to improve health related quality of life.
In an effort to harmonise existing disease staging systems,
the Global Initiative for Obstructive Lung Disease (GOLD)
included a novel classification of disease severity in their
guidelines.5 The GOLD classification has been developed by an
international panel of pulmonary experts and comprises four
stages, again based on FEV1. The approach of this unidimen-
sional staging system is pragmatic and the cut-off points
between stages differ from previous classifications, but are
still arbitrary.6 The GOLD classification has demonstrated its
usefulness already in longitudinal studies in which higher GOLD
stages were found to be associated with increased mortality
risk.7–9 Nevertheless, doubts exist about the appropriateness
of the GOLD classification to classify the impact of the disease
on health status adequately.10,11 Consequently, the clinical
utility of the GOLD classification for pulmonary rehabilitation
may be questioned. In a further attempt to evaluate the value
of the GOLD classification in pulmonary rehabilitation, the
present study investigated the discriminatory capacity for
outcomes of pulmonary function, exercise capacity, dyspnoea
and quality of life in COPD patients. In an additional analysis,
the discriminatory capacity of a multidimensional staging
system, i.e. the Body-Mass Index, Degree of Airflow Obstruc-
tion and Dyspnea, and Exercise Capacity Index (BODE index),
was assessed for quality of life.
Methods
GOLD classification of COPD disease severity
GOLD stages were defined as follows:
Stage I (mild): FEV1/forced vital capacity (FVC)o70% and
FEV1X80% predicted. With or without chronic symptoms
(cough, sputum production).Stage II (moderate): FEV1/FVCo70% and FEV1o80% pre-
dicted and X50% predicted. With or without chronic
symptoms (cough, sputum production).
Stage III (severe): FEV1/FVCo70% and FEV1o50% pre-
dicted and X30% predicted. With or without chronic
symptoms (cough, sputum production).
Stage IV (very severe): FEV1/FVCo70% and FEV1o30%
predicted or FEV1o50% predicted plus chronic respiratory
failure (PaO2o8.0 kPa with or without PaCO246.7 kPa while
breathing air at sea level).5
BODE index
The BODE index is a multidimensional index comprising the
body-mass index (B), the degree of airflow obstruction (O),
functional dyspnea (D), and exercise capacity (E) as assessed
by the 6 minute walk test (6 MWT). The BODE index ranges
from 0 to 10 points, with higher scores indicating a greater risk
of death. The BODE index can be divided in four quartiles,
quartile 1 is a score of 0–2, quartile 2 is a score of 3–4,
quartile 3 a score of 5–6, and quartile 4 a score of 7–10.12
Patients
We retrospectively reviewed a computerised database,
which included all pulmonary patients referred for an
outpatient pulmonary rehabilitation programme between
1998 and 2005. The rehabilitation programme was carried
out at the department of physical therapy of an academic
teaching hospital (VU University Medical Centre, Amster-
dam). Patients were referred by a pulmonary physician,
based on the presence of respiratory symptoms and/or
impaired exercise performance, despite optimal medical
treatment. Referred patients were using medication accord-
ing to the national guideline,13 and were in a stable
condition with a past period of acute exacerbation of at
least 6 weeks ago. Only patients with a clinical diagnosis of
COPD5 were included in this study. Since this study did not
alter patient care and was a retrospective study gathering
data, Institutional Review Board approval was not required,
and patient consent was not necessary. During the period
from January 1998 and January 2005, 1659 patients with
some form of obstructive lung disease consulted the
department of pulmonology. Ultimately, 253 patients were
included in this study. For patient selection see Figure 1.
Characteristics of included patients are summarised in
Table 1. Of the 253 COPD patients, 75 patients (30%) were
classified in GOLD II, 121 patients (48%) in GOLD III and 57
patients (22%) in GOLD IV. Four patients with a FEV1430%
but o50% were classified in GOLD IV as their PaO2
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N=1659 consulted the pulmonary 
department with some form of 
obstructive lung disease
N=1086 diagnosis COPD
N=76 excluded:
- n=43: heart failure, renal failure, a 
neurological or orthopaedic 
disorder as primary condition
- n=12: age <40 years
- n=21: <3 health status 
measurements
N=750 not referred for 
pulmonary rehabilitation
N=336 referred for pulmonary 
rehabilitation and underwent health 
status measurements
N=573 diagnosis asthma
Inclusion criteria:
- COPD as primary medical 
condition
- minimum age of 40 years
- besides spirometry, data of at 
least 3 other health status 
measurements
N=253 patients included in this study
N=7 exluded:
- n=7 patients classified with GOLD 
stage I
Figure 1 Flowchart patient selection.
Table 1 Patients’ characteristics.
Total (n ¼ 253)
Female, n (%) 84 (32%)
Age (yr) 66 (9)
BMI (kg/m2) 23.9 (4.1)
BMIo21, n (%) 60 (24%)
Post BD FEV1 (l) 1.2 (0.5)
Post BD FEV1 (% predicted) 44 (16)
Post BD FVC (l) 3.1 (1.0)
Post BD FVC (% predicted) 86 (20)
Post BD FEV1/FVC (%) 38 (12)
GOLD classification, n (%)
Stage II 75 (30%)
Stage III 121 (48%)
Stage IV 57 (22%)
BODE index, n (%)
Quartile 1 69 (33%)
Quartile 2 60 (29%)
Quartile 3 64 (30%)
Quartile 4 16 (8%)
Data are presented as n (%) or mean (s.d.). BD, bronchodi-
lator; BODE index, the Body-Mass Index, Degree of Airflow
Obstruction and Dyspnea, and Exercise Capacity Index; BMI,
body mass index; FEV1, forced expiratory volume in 1 s; FVC,
forced vital capacity.
R.J. Huijsmans et al.164o8.0 kPa.5 Of the total population, 32% was female. This
prevalence diminished considerably with increasing GOLD
stage (GOLD II ¼ 49%, GOLD III ¼ 30%, GOLD IV ¼ 13%,
po0.001). The average BMI was normal for the total
population, the percentage of patients who had a
BMIo21 kg/m2 rose with increasing GOLD stages (GOLD
II ¼ 17%, GOLD III ¼ 26%, GOLD IV ¼ 28%, p ¼ 0.001). FVC
decreased with increasing GOLD stage (po0.001). Due to
missing values, the BODE index was calculated in 209
patients (83%). Of those 209 patients, 69 patients (33%)
were in quartile 1 of the BODE index, 60 (29%) in quartile 2,
64 (30%) in quartile 3 and 16 patients (8%) in quartile 4. The
average age for the total population was 66 years, with a
minimum age of 42 and a maximum age of 86. Mean ages
between GOLD stages or BODE quartiles did not differ
significantly.
Health status measurements
All measurements were performed prior to the start of the
rehabilitation programme. Pulmonary function and an
incremental exercise test were performed in a pulmonary
function laboratory. All other measurements were carried
out in the department of physical therapy.
Pulmonary function
Pulmonary function was determined by a pulmonary
technician before and after inhalation of salbutamol
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functional residual capacity (FRC). FRC was assessed by body
plethysmography. The single-breath method using carbon
monoxide was used for the measurement of lung transfer
factor and normalised for alveolar volume (TLCO/va). All
measurements were made using standard equipment
(Vmax229 and 6200, Sensormedics, Yorba Linda, CA, USA)
and methodology according to the European Respiratory
Society recommendations.14 Measurements were related to
reference values of Quanjer et al.15 and Cotes et al.16
Arterial blood samples were obtained from the radial artery
for blood gas analysis (arterial oxygen pressure (PaO2) and
arterial carbon dioxide pressure (PaCO2)) at rest, breathing
room air (Rapidlab 840, Bayer AG, Leverkussen, Germany).
Exercise capacity
The 6 MWTwas performed according to the ATS guidelines.17
For every patient the test was repeated three times on
different days within a 2-week period. Best values were used
for further analysis. Results are expressed as percentage of
the predicted value.18
An incremental exercise test was conducted according
to the European Respiratory Society recommendations.19
The test was performed on a calibrated, electrically
braked cycle ergometer (WLP 904, Lode, Groningen, The
Netherlands) at a pedalling rate of 60 rpm. Workload was
increased every minute by 10% of the estimated maximal
workload until exhaustion. Peak oxygen uptake (VO2peak,
mlmin1 at standard temperature and pressure, and dry)
was measured with a breath-by-breath automated exercise
metabolic system (Vmax229, Sensormedics, Yorba Linda, CA,
USA). Within half an hour before the start of each test, the
airflow sensor was calibrated with a 3-L syringe and gas
analysers were calibrated against known gas concentrations.
Peak workload (Wpeak) and VO2peak were related to the
references of Jones et al.20 and Jones,21 respectively.
Dyspnoea
Dyspnoea was scored using the Medical Research Council
(MRC) dyspnoea scale. The MRC dyspnoea scale allows
classification of perceived breathlessness during daily
activities into five grades.22
Quality of life
Quality of life was measured with the St. George Respiratory
Questionnaire (SGRQ). This disease-specific questionnaire
evaluates symptoms (distress due to respiratory symptoms),
activities (the effects due to impairment of mobility or
physical activity), and impacts (the psychosocial impact of
the disease) plus a summary total score.23 For each subscale
and for the total score, scores range from 0% (no impair-
ment) to 100% (maximal impairment). Each item is weighted
using empirically derived weights. Lower scores indicate
improved health status, and a change of 4 in total score (out
of 100) is considered clinically meaningful.24 Results are
expressed as a percentage of the maximum score.
Statistical analysis
For the GOLD classification all health status outcomes,
including BMI, FEV1, MRC and 6 MWT, were included in theanalysis. For the BODE index only the outcomes of the SGRQ
were analysed as the BODE index is a composite of BMI,
FEV1, MRC and 6 MWT. Distributions of health status
outcomes were analysed by means of the Kolmogorov–Smir-
nov test, and by viewing frequency distributions plots for
normality. Homogeneity of variance was tested with the
Levene test. Differences in health status outcomes among
GOLD stages and BODE quartiles were analysed to determine
the discriminatory capacity of these classifications. A One
Way Analysis of Variance (ANOVA) was used for indexes with
both normal distribution and homogeneous variance. Post
hoc differences between stages were assessed by the
Scheffe` test. A Kruskal Wallis test was performed for indexes
lacking normal distribution and/or homogeneous variance
and post hoc differences between stages were assessed
using the Mann–Whitney U test. Subsequently, scatterplots
were produced for all outcomes. Relationships between
FEV1 and health status outcomes and between BODE index
and quality of life were analysed. Pearson’s product–mo-
ment correlation test was used for indexes with normal
distribution, and a Spearman’s rank correlation test for
indexes lacking normal distribution. Overlap in health status
outcomes between GOLD stages was identified using
clinically meaningful cut-off points. For pulmonary
function, the number of patients in each GOLD stage with
a TLCO/vao50%, which is associated with exercise induced
hypoxaemia,25 was described. For exercise capacity, the
number of patients with a walking distance on the 6 MWT
less than 300m, which is significantly related to a lower
survival rate, was described.26,27 For quality of life, the
minimal clinically meaningful difference was used to
describe the overlap in scores. The number of patients with
at least four points higher total score compared to the
average score in the preceding GOLD stage or preceding
BODE quartile was identified. For all tests, SPSS Advanced
Statistics 15.0 for Windows (SPSS Inc., Chicago, IL) was
applied, using a two-sided significance level of 0.05.
Results
Values of health status outcomes for each GOLD stage and
results of analyses of variance are presented in Table 2.
Values of SGRQ for each BODE quartile and results of
analyses of variance are given in Table 3.
Pulmonary function
Analyses of variance for the GOLD classification were
statistically significant for FRC, TLCO/va, PaO2 and PaCO2.
Post hoc analysis showed statistically significant differences
for FRC, TLCO/va and PaO2 between GOLD stages II and III and
between GOLD stages II and IV, but not between stages III
and IV. For the outcome of PaCO2 a statistically significant
difference was found between all stages. Scatterplots of
pulmonary function outcomes are presented in Figure 2.
Correlations between FEV1 and FRC, TLCO/va, PaO2
and PaCO2 were statistically significant and ranged between
0.32 and 0.47. Large variability in values and overlap
between GOLD stages is seen in all outcomes. Patients with
a TLCO/vao50% were present in all stages, 39% in stage IV, 35%
in stage III and 17% in stage II.
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Table 2 Health status outcomes for different GOLD stages.
GOLD II GOLD III GOLD IV p-Value
(n ¼ 75) (n ¼ 121) (n ¼ 57) (ANOVA/Kruskal Wallis)
Pulmonary function
FRC (% predicted) 133 (30) 159 (34) 171 (34)y o0.001
TLCO/va (% predicted) 72 (25)
 56 (22) 52 (21)y o0.001
PaO2 (kPa) 11.0 (1.3)
 10.0 (1.5) 9.4 (1.5)y o0.001
PaCO2 (kPa) 5.0 (0.5)
 5.3 (0.6)z 5.7 (0.8)y o0.001
Exercise capacity
6 MWT (% predicted) 76 (14) 67 (17)z 54 (17)y o0.001
Wpeak (% predicted) 67 (21) 54 (18)z 35 (16)y o0.001
VO2peak (% predicted) 69 (20)
 58 (16)z 45 (11)y o0.001
BODE index
1.0 (0.0–4.0) 4.0 (1.0–8.0)z 6.0 (3.0–9.0)y o0.001
Dyspnoea
MRC 2.0 (1.0–4.0) 3.0 (1.0–5.0)z 4.0 (2.0-5.0)y o0.001
Quality of life
SGRQ symptoms (% maximum score) 56 (23) 55 (22) 50 (23) 0.46
SGRQ activities (% maximum score) 67 (16) 72 (16)z 80 (14)y 0.001
SGRQ impacts (% maximum score) 41 (17) 43 (18) 49 (20) 0.12
SGRQ total (% maximum score) 51 (15) 54 (15) 59 (14) 0.10
Values are mean (s.d.) except for MRC and BODE index, which are expressed as median (range). BODE index, the Body-Mass Index,
Degree of Airflow Obstruction and Dyspnea, and Exercise Capacity Index; FRC, functional residual capacity; MRC, medical research
council; 6 MWT, 6min walk test; PaCO2, arterial carbon dioxide pressure; PaO2, arterial oxygen pressure; SGRQ, St. George Respiratory
Questionnaire; TLCO/va, lung transfer factor normalised for alveolar volume; VO2peak, peak oxygen uptake; Wpeak, peak workload.
Significant difference between GOLD stages II and III.
ySignificant difference between GOLD stages II and IV.
zSignificant difference between GOLD stages III and IV.
Table 3 Health status outcomes for the four quartiles of the Body-Mass Index, Degree of Airflow Obstruction and Dyspnea,
and Exercise Capacity Index.
Quartile 1
(n ¼ 69)
Quartile 2
(n ¼ 60)
Quartile 3
(n ¼ 64)
Quartile 4
(n ¼ 16)
p-Value (ANOVA/
Kruskal Wallis)
Quality of life
SGRQ symptoms (% maximum score) 57 (23) 54 (20) 54 (24) 50 (26) 0.79
SGRQ activities (% maximum score) 64 (16) 71 (16)y 77 (11) 89 (6)z o0.001
SGRQ impacts (% maximum score) 40 (17) 41 (17) 47 (17) 55 (19) 0.04
SGRQ total (% maximum score) 50 (15) 52 (14) 57 (14) 64 (12)z 0.01
Values are mean (s.d.). SGRQ, St. George Respiratory Questionnaire.
Significant difference between quartiles 1 and 3.
ySignificant difference between quartiles 2 and 4.
zSignificant difference between quartiles 1 and 4.
R.J. Huijsmans et al.166Exercise capacity and dyspnoea
Analyses of variance for the GOLD classification were
statistically significant for 6 MWT, Wpeak, VO2peak as well
as for the dyspnoea score on the MRC. Post hoc analyses of
differences between GOLD stages showed statisticallysignificant differences for consecutive and non-consecutive
stages in all outcomes. Scatterplots of exercise capacity and
dyspnoea are presented in Figure 3. Correlations between
FEV1 and 6 MWT,Wpeak, VO2peak and MRC were statistically
significant and ranged between 0.43 and 0.73. Wide scatter
and marked overlap between stages was found for all
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Figure 3 Relationships between FEV1 (% predicted) and outcomes of exercise capacity and dyspnoea. (A) 6min walk test (6 MWT)
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The GOLD classification in pulmonary rehabilitation 167outcomes. For the 6 MWT, there was a moderate number in
each GOLD stage who walked less than 300m. In stage IV,
18% of the patients walked less than 300m, in stage III 13%and in stage II, 8% of the patients. Large variability is as well
present in the outcome of MRC, where for instance, scores
of patients in GOLD stage III varied between 1 and 5.
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GOLD classification
Analysis of variance for the GOLD classification was merely
statistically significant for the activities section of the SGRQ.
No significant differences were found for the symptom
section (p ¼ 0.46), the impacts section (p ¼ 0.12) and for
the total score (p ¼ 0.10) of the SGRQ. Post-hoc analysis
showed a significant difference in the activities section,
between GOLD stages II and IV, and between GOLD stages III
and IV. The total score demonstrated a clinically meaningful
but not a statistically significant difference between GOLD
stages III and IV.
Scatterplots of quality of life outcomes are presented
in Figure 4. Correlations between FEV1 and the activities
section, impacts section and total score of the SGRQ
were statistically significant and ranged between 0.19
and 0.34. No statistically significant correlation was found
for the symptoms sections. Once more, large variability
in scores and overlap between stages is seen. In stage III,
only 27% of the patients had a four points higher total
score or more than the average score in stage II. And in
stage IV, 30% of the patients had a meaningful
important different score compared to the average score
in stage III.BODE index
Analysis of variance for the BODE index was statistically
significant for the activities, impacts and the total score of
the SGRQ. No significant difference was found for the
symptom section (p ¼ 0.79). Post-hoc analysis showed a
significant difference in the activities section, between
quartiles 1 and 4, quartiles 1 and 3 and quartiles 2 and 4. For0
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Figure 4 Relationships between FEV1 (% predicted) and outcomes
(SGRQ). (A) SGRQ symptoms [NS], (B) SGRQ activities [r ¼ 0.34, p
total score [r ¼ 0.21, p ¼ 0.01].m: patients with a FEV1430% class
mean values for each GOLD stage. Data are percentages of maximuthe impacts section no significant differences were found
between quartiles. For the total score only quartiles 1 and 4
differed significantly. A clinically meaningful difference of
at least four point of the total score was found between all
quartiles except between 1 and 2. Scatterplots of quality of
life outcomes are presented in Figure 5. Correlations
between BODE index and the activities section, impacts
section and total score of the SGRQ were statistically
significant and ranged between 0.23 and 0.45. No statisti-
cally significant correlation was found for the symptoms
sections. Also for the BODE index, large variability in scores
and overlap in quartiles is seen.Discussion
This study demonstrated that the GOLD classification is able
to discriminate disease severity between COPD patients in
important rehabilitation outcomes, such as pulmonary
function, exercise capacity and dyspnoea. For the outcome
of quality of life, discriminatory capacity was found only for
the activities section of the SGRQ. The BODE index showed
slightly better discriminatory capacity for the outcome of
quality of life, not only for the activities section but also for
the impacts section and total score of the SGRQ. As the
GOLD staging criteria distinguishes groups of patients with
various degrees of impairment in these health status
outcomes, boundaries between stages set by the GOLD
committee seem appropriate. However, it must be noted
that, on an individual basis, wide scatter and considerable
overlap between stages was found for all outcomes. With
respect to the discriminatory capacity of the GOLD
classification, these findings show that the GOLD classifica-
tion indeed can be used to discern groups of COPD patients,0
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The GOLD classification in pulmonary rehabilitation 169but it does not seem adequate as a basis for individual
management plans in rehabilitation.
From the results of the present study it appeared that
large inter-individual variability was observed within GOLD
stages for all health status outcomes. Individuals in stage II
may have similar impairments in diffusion capacity, hyper-
inflation, exercise capacity and quality of life as patients in
stage IV. The correlation between the GOLD classification
and dyspnoea, reduced exercise tolerance or quality of life
is as poor that the classification cannot be useful in the
selection of candidates for pulmonary rehabilitation or
defining treatment targets for individual rehabilitation
programs. Results from this study do not provide information
regarding the responses of patients to rehabilitation among
GOLD stages. This certainly is an interesting topic for further
research.28
Another finding in this study was that the GOLD
classification has better discriminatory capacity for lung
function impairment and exercise capacity compared to
outcomes of quality of life. This may not be surprising
since quality of life is a complex multidimensional assess-
ment which encompasses many facets and therefore is not
likely to be explained by one single physiological parameter
such as FEV1. Also other variables, or a combination of
variables such as the BODE index, failed to explain the
outcome of health related quality of life to a satisfactory
level.23,29 This was confirmed in the present study. As
optimatisation of quality of life is an important goal for
rehabilitation in COPD patients, it seems necessary to
measure quality of life in each patient, independent of the
GOLD stage severity or BODE index. Not only to provide an
overall view of the disease impact in the individual, but alsofor treatment evaluation where quality of life is a relevant
outcome.
In previous studies, it has been suggested that the
boundary between GOLD stages II and III (FEV1o50%) marks
a threshold for dramatic worsening of health status and an
increased mortality risk.7,30 Indeed, in this study, the largest
reduction in FRC, TLCO/va and PaO2 was seen in the
transition from GOLD II to GOLD III. But, the largest
reduction in exercise capacity and quality of life was found
in the transition from GOLD III to GOLD IV. The dissociation in
worsening between lung function on the one hand, and
deteriorations in exercise capacity and quality of life on the
other, underscores the independence of changes in these
outcomes. Moreover, our findings and those from others31 do
not sustain the general assumption that patients with an
FEV1 over 50% predicted should have minimal impairment in
exercise capacity or quality of life. Even in stage II
deterioration in these outcomes may be clearly manifest,
and these patients could be indicated for pulmonary
rehabilitation.
The present study shows that a unidimensional staging
system based on FEV1 poorly reflects the overall disease
impact in COPD patients. To get a more comprehensive view
on this heterogeneous disease, a multidimensional grading
system such as the BODE index could be more appropriate.
The BODE index includes FEV1, 6 MWT, MRC dyspnoea score
and BMI, variables significantly associated with survival in
COPD patients, and proved to be a better predictor of
mortality in COPD patients than FEV1.
12 The results in this
study show that the BODE index is also a better predictor of
quality of life because a stronger association was found
between the BODE index and quality of life (r ¼ 0.23–0.45)
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However, the unexplained variance still remains significant.
Our study has a few drawbacks. We had few data on
patients classified in GOLD stage I. These patients are rarely
identified and therefore hardly ever referred to an out-
patient pulmonary clinic. In the study by Kohler et al.32 only
4–5% of a population of a 1000 COPD patients was classified
in GOLD I. They concluded that there was an inhomogeneous
distribution of patients among GOLD stages. In this study, we
had data of only seven patients classified in GOLD I and they
were for this reason excluded. Therefore, we cannot draw
conclusions with respect to the clinical utility of the GOLD
classification in rehabilitation for GOLD stage I.
The health status measurements chosen in this study are
an arbitrary and limited set of outcomes. Although they
cover a comprehensive part of important variables in COPD
rehabilitation, they do not include other potentially
important characteristics, such as respiratory or peripheral
muscle function or nutritional status. The present study also
lacks information about co-morbidity, exacerbation fre-
quency, medication use, or hospitalisation. It is known that
features as co-morbidity may affect the course of COPD,33
and it cannot be ruled out that investigations into these
latter outcomes may lead to different conclusions about the
clinical utility of the GOLD classification or the BODE index.
In conclusion, the GOLD classification of COPD disease
severity has discriminatory capacity on group level for
outcomes of pulmonary function, exercise capacity and
dyspnoea. The classification is widespread and well under-
stood, and therefore useful as a way of sharing consensus in
terminology. Unfortunately, the GOLD classification is not
useful as a clinical tool for decision making in the
rehabilitation of the individual COPD patient. Although the
BODE index shows a somewhat better discriminatory
capacity for quality of life, individual assessments on all
clinical areas of relevance will continue to be required in
order to define adequate treatment descriptions.References
1. Standards for the diagnosis and care of patients with chronic
obstructive pulmonary disease. American Thoracic Society. Am
J Respir Crit Care Med 1995;152(5 Pt 2):S77–S121.
2. BTS guidelines for the management of chronic obstructive
pulmonary disease. The COPD guidelines Group of the Standards
of Care Committee of the BTS. Thorax 1997;52(Suppl 5):S1–S28.
3. Celli BR. Current thoughts regarding treatment of chronic
obstructive pulmonary disease. Med Clin North Am 1996;80:
589–609.
4. Agustı´ AG. COPD, a multicomponent disease: implications for
management. Respir Med 2005;99:670–82.
5. Pauwels RA, Buist AS, Calverly PM, Jenkins CR, Hurd SS. Global
strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease. NHLBI/WHO Global
Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop
summary. Am J Respir Crit Care Med 2001;163:1256–76.
6. Calverley PM. The GOLD classification has advanced under-
standing of COPD. Am J Respir Crit Care Med 2004;170:211–2.
7. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on
Obstructive Lung Disease (GOLD) classification of lung disease
and mortality: findings from the Atherosclerosis Risk in
Communities (ARIC) study. Respir Med 2006;100:115–22.8. Ekberg-Aronsson M, Pehrsson K, Nilssson JA, Nilsson PM, Lofdahl
CG. Mortality in GOLD stages of COPD and its dependence on
symptoms of chronic bronchitis. Respir Res 2005;6:98.
9. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF.
Body composition and mortality in chronic obstructive pulmon-
ary disease. Am J Clin Nutr 2005;82:53–9.
10. Kerstjens HA. The GOLD classification has not advanced under-
standing of COPD. Am J Respir Crit Care Med 2004;170:212–3.
11. The Global Strategy for the Diagnosis, Management and
Prevention of COPD, Global Initiative for Chronic Obstructive
Lung Disease (GOLD) 2006. Available from: /http://www.
goldcopd.orgS. Date last accessed: July 10, 2007.
12. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow
obstruction, dyspnea, and exercise capacity index in chronic
obstructive pulmonary disease. N Engl J Med 2004;350:1005–12.
13. Halpin D. NICE guidance for COPD. Thorax 2004; 59:181–2.
14. Standardized lung function testing. Official statement of the
European Respiratory Society. Eur Respir J Suppl 1993;16:1–100.
15. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R,
Yernault JC. Lung volumes and forced ventilatory flows. Report
Working Party Standardization of Lung Function Tests, European
Community for Steel and Coal. Official Statement of the
European Respiratory Society. Eur Respir J Suppl 1993;16:5–40.
16. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC.
Standardization of the measurement of transfer factor (diffu-
sion capacity). Report Working Party Standardization of Lung
Function Tests, European Community for Steel and Coal. Official
Statement of the European Respiratory Society. Eur Respir J
Suppl 1993;16:41–52.
17. ATS Committee on Proficiency Standards for Clinical Pulmonary
Function Laboratories. ATS Statement: guidelines for the six-
minute walk test. Am J Resp Crit Care Med 2002;166:111–7.
18. Troosters T, Gosselink R, Decramer M. Six minute walking
distance in healthy elderly subjects. Eur Respir J 1999;14:
270–4.
19. Clinical exercise testing with reference to lung diseases:
indications. Standardization and interpretation strategies. ERS
Task Force on Standardization of Clinical Exercise Testing.
European Respiratory Society. Eur Respir J 1997;10:2662–89.
20. Jones NL, Summers E, Killian KJ. Influence of age and stature on
exercise capacity during incremental cycle ergometry in men
and women. Am Rev Respir Dis 1989;140:1373–80.
21. Jones NL. Normal values for pulmonary gas exchange during
exercise. Am Rev Respir Dis 1984;129:S44–6.
22. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha
JA. Usefulness of the Medical Research Council (MRC) dyspnoea
scale as a measure of disability in patients with chronic
obstructive pulmonary disease. Thorax 1999;54:581–6.
23. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-
complete measure of health status for chronic airflow limita-
tion. The St. George Respiratory Questionnaire. Am Rev Respir
Dis 1992;145:1321–7.
24. Jones PW. Interpreting thresholds for a clinically significant
change in health status in asthma and COPD. Eur Resp J 2002;
19:398–404.
25. Nordenfelt I, Svensson G. The transfer factor (diffusing
capacity) as a predictor of hypoxaemia during exercise in
restrictive and chronic obstructive pulmonary disease. Clin
Physiol 1987;7:423–30.
26. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min
walk distance: change over time and value as a predictor of
survival in severe COPD. Eur Respir J 2004;23:28–33.
27. Bowen JB, Votto JJ, Thrall RS, et al. Functional status and
survival following pulmonary rehabiliation. Chest 2000;118:
697–703.
28. Takigawa N, Tada A, Soda R, et al. Comprehensive pulmonary
rehabilitation according to severity of COPD. Respir Med
2007;101:336–432.
ARTICLE IN PRESS
The GOLD classification in pulmonary rehabilitation 17129. Ketelaars CA, Schlosser MA, Mostert R, Huyer Abu-Saad H,
Halfens RJ, Wouters EF. Determinants of health related quality
of life in patients with chronic obstructive pulmonary disease.
Thorax 1996;51:39–43.
30. Antonelli-Incalzi R, Imperiale C, Bellia V, et al. Do GOLD stages
of COPD disease severity really correspond to differences in
health status? Eur Respir J 2003;22:444–9.
31. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive
pulmonary disease stage and health related quality of life.The quality of life of chronic obstructive pulmonary disease
study group. Ann Intern Med 1997;127:1072–9.
32. Ko¨hler D, Fisher J, Raschke F, Scho¨nhofer B. Usefulness
of GOLD classification of COPD severity. Thorax 2003;58:
825.
33. Wijnhoven HA, Kriegsman DM, Hesselink AE, de Haan M,
Schellevis FG. The influence of co-morbidity on health related
quality of life in asthma and COPD patients. Respir Med
2003;97:468–75.
